Organon &

Organon & Assets per Share

The Total Assets per Share of Organon & (OGN) as of Nov 3, 2026 is 49.49 USD. In the previous year, Total Assets per Share was 50.39 USD — a change of -1.79% (lower).

Assets per Share

49.49USD

YoY

-1.79%

Last updated:

Total Assets per Share of Organon & is 2025 49.49 USD. Total Assets per Share of Organon & was 2024 50.39 USD. It decreases by -1.79% lower compared to the previous year.

The Organon & Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2018
40.36 USD
Jan 1, 2019
40.57 USD
Jan 1, 2020
38.88 USD
Jan 1, 2021
41.08 USD
Jan 1, 2022
42.14 USD
Jan 1, 2023
46.38 USD
Jan 1, 2024
50.39 USD
Jan 1, 2025
49.49 USD
The Organon & Assets per Share history
YEARAssets per ShareYoY
49.49USD-1.79%
50.39USD+8.65%
46.38USD+10.07%
42.14USD+2.57%
41.08USD+5.66%
38.88USD-4.16%
40.57USD+0.51%
40.36USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Organon & Stock analysis

What does Organon & do? Organon & Co. generates revenue through prescription therapies and medical devices focused on women’s health, biosimilars, and established brands. Key products include contraception and fertility solutions like Nexplanon, Implanon NXT, NuvaRing, Follistim AQ, and Elonva, alongside biosimilars for immunology and oncology. Established brands cover cardiovascular, respiratory, dermatology, and non-opioid pain management segments. The company sells directly to drug wholesalers, retailers, hospitals, government agencies, and managed healthcare providers such as health maintenance organizations and pharmacy benefit managers. Organon’s portfolio targets healthcare institutions and providers, with products distributed through established pharmaceutical channels. The company’s biosimilars and women’s health brands drive sales in specialized medical markets, while established brands serve broader therapeutic areas. Revenue streams are derived from direct sales to healthcare systems and institutions that manage patient care across multiple therapeutic categories. The firm’s strategy centers on delivering innovative health solutions via a diversified product portfolio. Prescription therapies for women’s health, including contraceptive and fertility treatments, form a significant segment of sales. Biosimilars in immunology and oncology, alongside established brands in cardiovascular and respiratory care, contribute to recurring revenue from institutional buyers. Organon & is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Organon & stock

Total Assets per Share of Organon & is 49.49 USD in 2025.

Total Assets per Share of Organon & changed from 50.39 USD to 49.49 USD, representing a -1.79% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share Organon & since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Organon &

All Key Metrics — Organon &